A prospective study to assess the screening value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for the identification of patients that benefit from additional cardiac testing prior to vascular surgery.

A prospective study to assess the screening value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for the identification of patients that benefit from additional cardiac testing prior to vascular surgery. - DECREASE VI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30697

Enrollment

1000

Registered

2007-02-21

Start date

2007-08-22

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative cardiac risk stratification

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with peripheral vascular atherosclerosis scheduled for vascular surgery involving either; a) revascularization utilizing aortic or proximal lower extremity procedures, or b) distal lower extremity vascular reconstruction, are eligible to participate.

Exclusion criteria

Exclusion criteria: No written informed consent. Unstable coronary disease. Undergoing emergency surgery. Previous participation in the DECREASE VI trial. Reoperation within 30 days of an initial surgical procedure. Participation in another clinical trial within the last 30 days. Age

Design outcomes

Primary

Measure	Time frame
The primary objective of this trial is to validate the screening potential of NT-proBNP in a population of low to intermediate risk patients, i.e. patients with zero to two cardiac risk factors, scheduled for vascular surgery.	—

Secondary

Measure	Time frame
The secondary objective is to identify prior to vascular surgery high risk patients, with three or more cardiac risk factors, with a normal stress test.	—

Countries

Netherlands

Outcome results